Welcome to our dedicated page for Atossa Therapeutics news (Ticker: ATOS), a resource for investors and traders seeking the latest updates and insights on Atossa Therapeutics stock.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company whose news flow centers on the development of its lead investigational therapy, (Z)-Endoxifen. Company announcements frequently cover progress in breast cancer programs, regulatory interactions, intellectual property developments, and emerging opportunities in other serious diseases.
Investors following ATOS news can expect regular updates on clinical trials involving (Z)-Endoxifen, including studies in metastatic ER+/HER2- breast cancer, neoadjuvant treatment for premenopausal ER+/HER2- patients, breast cancer risk reduction strategies focused on mammographic breast density, and participation in the RECAST DCIS platform trial for hormone receptor–positive ductal carcinoma in situ. These releases often summarize trial design, early findings, and the potential implications for future registration strategies.
Atossa’s news also highlights regulatory milestones, such as FDA Type C meetings, Investigational New Drug (IND) submissions, and “Study May Proceed” letters. Additional coverage includes the FDA’s Rare Pediatric Disease designation for (Z)-Endoxifen in Duchenne Muscular Dystrophy, as well as AI-enabled research collaborations identifying new oncology indications like glioblastoma.
Another recurring theme in ATOS news is the company’s intellectual property position, including newly issued patents for enteric oral (Z)-Endoxifen formulations and methods of use in hormone-dependent breast disorders and estrogen-related conditions. Corporate updates, such as financial results, leadership appointments, and Nasdaq listing communications, provide context on Atossa’s operational and strategic direction.
By monitoring this news page, readers can review a chronological record of Atossa’s clinical, regulatory, scientific, and corporate announcements related to (Z)-Endoxifen and the company’s broader oncology and rare disease programs.
Atossa Therapeutics (ATOS) reported its Q1 2020 financial results, revealing no sustainable revenue and total operating expenses of approximately $2.94 million, down 28% from Q1 2019. Key developments include the launch of the COVID-19 HOPE program to test AT-H201, aiming to improve lung function in COVID-19 patients. Positive interim results from the Phase 2 study of oral Endoxifen indicated a 74% reduction in tumor cell proliferation. The company is planning further clinical trials, with approximately $9.4 million in cash as of March 31, 2020.
Atossa Therapeutics (NASDAQ: ATOS) announced positive interim results from its Phase 2 study of oral Endoxifen for breast cancer, reporting a statistically significant 74% reduction in tumor cell proliferation (p = 0.031) over 22 days. All six patients showed a decrease in Ki-67, a key proliferation marker, with levels dropping below 25%. The study, conducted in Australia, aims to enroll 25 patients, and successful results may lead to a Phase 3 study. There were no safety concerns noted, and patients reported fewer side effects compared to traditional therapies.